Optimal aspirin dose in acute coronary syndromes: an emerging consensus.

about

P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use

P2860

Q38542096-A6C2A6FB-549C-4759-A974-882F110E3071

P2860

Optimal aspirin dose in acute coronary syndromes: an emerging consensus.

Item

http://www.wikidata.org/entity/Q38206844

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Optimal aspirin dose in acute coronary syndromes: an emerging consensus.

@en

type

Item

label

Optimal aspirin dose in acute coronary syndromes: an emerging consensus.

@en

prefLabel

Optimal aspirin dose in acute coronary syndromes: an emerging consensus.

@en

P1476

Optimal aspirin dose in acute coronary syndromes: an emerging consensus

@en

P2093

Asfandyar K Niazi

http://www.w3.org/2001/XMLSchema#string

Carl J Lavie

http://www.w3.org/2001/XMLSchema#string

Enrico Cerrato

http://www.w3.org/2001/XMLSchema#string

Fabrizio D'Ascenzo

http://www.w3.org/2001/XMLSchema#string

James H O'Keefe

http://www.w3.org/2001/XMLSchema#string

James J DiNicolantonio

http://www.w3.org/2001/XMLSchema#string

Kathleen A Packard

http://www.w3.org/2001/XMLSchema#string

Pascal Meier

http://www.w3.org/2001/XMLSchema#string

Saurav Chatterjee

http://www.w3.org/2001/XMLSchema#string

Victor L Serebruany

http://www.w3.org/2001/XMLSchema#string

P2860

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

Aspirin resistance: current status and role of tailored therapy

Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes

Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study

Aspirin dose and six-month outcome after an acute coronary syndrome

Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

Aspirin dosage and thromboxane synthesis in patients with vascular disease

Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease

Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery

P304

291-300

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FCA.14.7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sripal Bangalore

Nicholas B Norgard

Giuseppe Biondi-Zoccai

Flavio D Fuchs

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261880894

http://www.w3.org/2001/XMLSchema#string

P698

24762255

http://www.w3.org/2001/XMLSchema#string

P921

aspirin

Optimal aspirin dose in acute coronary syndromes: an emerging consensus.

about

P2860

P2860

Optimal aspirin dose in acute coronary syndromes: an emerging consensus.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921